Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.

MLA

O’Reilly, Terry, et al. “Evaluation of the MTOR Inhibitor, Everolimus, in Combination with Cytotoxic Antitumor Agents Using Human Tumor Models in Vitro and in Vivo.” Anti-Cancer Drugs, vol. 22, no. 1, Jan. 2011, pp. 58–78. EBSCOhost, https://doi.org/10.1097/CAD.0b013e3283400a20.

APA

O’Reilly, T., McSheehy, P. M. J., Wartmann, M., Lassota, P., Brandt, R., & Lane, H. A. (2011). Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo. Anti-Cancer Drugs, 22(1), 58–78. https://doi.org/10.1097/CAD.0b013e3283400a20

Chicago

O’Reilly, Terry, Paul M J McSheehy, Markus Wartmann, Peter Lassota, Ralf Brandt, and Heidi A Lane. 2011. “Evaluation of the MTOR Inhibitor, Everolimus, in Combination with Cytotoxic Antitumor Agents Using Human Tumor Models in Vitro and in Vivo.” Anti-Cancer Drugs 22 (1): 58–78. doi:10.1097/CAD.0b013e3283400a20.